CTNM

Contineum Therapeutics
CTNM

Upgrade to unlock
Buy
Hold
Sell

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
Avg. target
$14
3% upside
High target

1 analyst rating

positive
1  neutral
100%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
Morgan Stanley
Morgan Stanley
Jeffrey Hung
67% 1-yr CTNM win rate
8 Jan ‘26 1 month ago